GlycoErase™ POMGNT2 Knockout Human Prostate Cancer Cell 22RV1 (CAT#: GLJF-0525-JF330)

Description	The POMGNT2-deficient human prostate cancer cell line 22RV1 allows for the exploration of a glycosyltransferase of unknown function in prostate cancer; further research is required to elucidate the specific impacts of POMGNT2 loss in these cells.
Product Type	KO Cell Lines
Species	Human
Cell Morphology	Epitheloid cells, adherent
Passage Ratio	1:3~1:10
Cell Line	22RV1
Primary Disease	Prostate Adenocarcinoma
Lineage	Prostate

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	DMEM & FBS & RPMI
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	POMGNT2
Full Name	Protein O-linked mannose O-acetylglucosaminyltransferase 2 (Beta 1,4-)
Alternative Name	GTDC2, AGO61, C3orf39, FLJ14566
Location	3p22.1
Gene ID	84892
Summary	Predicted glycosyltransferase with yet-to-be-characterized function in glycosylation pathways.